Traders Purchase High Volume of ALT5 Sigma Call Options (NASDAQ:ALTS)

ALT5 Sigma Corporation (NASDAQ:ALTS) was the target of unusually large options trading activity on Monday. Stock investors bought 5,152 call options on the company. This represents an increase of 198% compared to the average daily volume of 1,727 call options.

Institutional Investors Weigh In On ALT5 Sigma

Institutional investors have recently bought and sold shares of the stock. Bridgeway Capital Management LLC grew its stake in shares of ALT5 Sigma by 9.4% during the 2nd quarter. Bridgeway Capital Management LLC now owns 19,339 shares of the company’s stock valued at $140,000 after buying an additional 1,661 shares during the period. Caitong International Asset Management Co. Ltd lifted its stake in shares of ALT5 Sigma by 23.9% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 45,322 shares of the company’s stock valued at $50,000 after purchasing an additional 8,742 shares in the last quarter. Profund Advisors LLC acquired a new position in shares of ALT5 Sigma in the 3rd quarter valued at about $28,000. Arete Wealth Advisors LLC purchased a new stake in shares of ALT5 Sigma during the 3rd quarter worth about $28,000. Finally, Geode Capital Management LLC grew its holdings in shares of ALT5 Sigma by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 1,331,963 shares of the company’s stock worth $1,466,000 after purchasing an additional 12,400 shares during the period. 6.27% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of ALT5 Sigma in a research report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.

ALT5 Sigma Stock Down 0.9%

NASDAQ ALTS opened at $1.11 on Wednesday. The business’s 50-day moving average price is $1.57 and its 200 day moving average price is $1.92. The company has a current ratio of 0.79, a quick ratio of 0.79 and a debt-to-equity ratio of 0.01. ALT5 Sigma has a twelve month low of $1.00 and a twelve month high of $10.95.

ALT5 Sigma (NASDAQ:ALTS) last posted its quarterly earnings results on Monday, January 12th. The company reported $0.29 EPS for the quarter. ALT5 Sigma had a return on equity of 8.60% and a net margin of 133.06%.The company had revenue of $7.58 million during the quarter.

ALT5 Sigma Company Profile

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties.